Day: August 2, 2019

Investigational ASOs for Huntington’s disease and for ALS are in Phase 3 clinical trials. In some cases, ASOs silence the mutant allele of a gene while allowing expression of the good copy. In other cases—and this is relevant to DIAN families—an ASO simply reduces the overall expression of a gene whose protein is part of the disease process.